Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 91 for “"Tau aggregation"”.
-
Tau Aggregation, Conformational Selection, and Inhibition
Tau fibrils are a pathological hallmark of over 20 neurodegenerative disorders, including Alzheimer's disease. There currently is no cure for these diseases and treatments are limited. Once Tau fibrils form in the brain, they propagate down neuronal networks, and this spreading is linked to disease …
-
Current state of tau aggregation inhibitors
Tau is an intrinsically disordered, heat stable, and highly soluble protein found primarily in the axons of the central nervous system. It belongs to the family of structural microtubule-associated proteins, the major function of which is promoting and stabilizing microtubule assembly. However, …
-
Function within Disorder: HSPB1 and HSPB5 Modulate Tau Aggregation
… diseases, microtubule-associated protein tau forms fibrillar aggregates that are hallmarks of disease pathology. Small heat shock proteins (sHSPs) are ATP-independent molecular chaperones that play a critical role in maintaining protein homeostasis. Two sHSPs, HSPB1 (Hsp27) and HSPB5 …
-
Screening for Tau Aggregation Inhibitors Using a NanoLuciferase Binary Technology
Tauopathies are neurodegenerative disorders characterized by accumulating misfolded, insoluble tau protein aggregates in neurons or glial cells. These diseases manifest in various clinical symptoms, including cognitive, behavioral, movement, and language issues. While neurofibrillary tangles (NFTs) …
-
The Role of DnaJC7 in Modulating Tau Aggregation in the Cell
Tauopathies are a diverse group of neurodegenerative diseases characterized by the abnormal accumulation of misfolded tau protein. The most recognized tauopathy, Alzheimer's Disease, is estimated to affect more than 30 million people worldwide. Mutations that increase the propensity for tau to …
-
Investigating the Potential Role of α-Synuclein in Tau Aggregation and Toxicity
… by the presence of intracellular abnormal aggregation of α-Synuclein (α-Syn) in Lewy bodies (LBs) and Lewy neurites (LNs), are collectively known as synucleinopathies. Even so, tau protein pathology is abundantly found in these diseases. Apart from Parkinson’s disease (PD), dementia with …
-
Development of a HEK293 Cell Line to Show Inhibition of Tau Aggregation
Intracellular deposition of aggregated tau is the hallmark of several different tauopathies, the most widespread of these being Alzheimer's disease. Tau is a highly soluble, intrinsically disordered, microtubule associated protein. Tau's native function is to stabilize microtubule formation in the …
-
Characterization of a Novel Tau Aggregation Inhibitor Isolated from Fungal Secondary Metabolites
… cost of care is billions of dollars per year. Tau aggregation is a pathological hallmark in neurodegenerative diseases known as tauopathies, which includes Alzheimer’s disease. Currently there are no approved drugs that can inhibit or reverse tau aggregation. Natural products, such as ones …
-
Modulation der Tau-Aggregation durch Modifikation der Cystein-Reste im Tau-Protein
Tauopathien sind Krankheiten, die mit einer abnormen intrazellulären Tau-Protein-Faltung, Tau-Protein-Aggregation und Filament-Bildung im ZNS und PNS einhergehen. Die Alzheimer Demenz stellt die häufigste Tauopathie dar. Bei ihr kommt es zu einer intra- und extrazellulären Ablagerung fehlgefalteter …
-
Mechanistic Investigation into the Regulation of Amyloid Motifs in Tau Aggregation and Disease
Amyloid formation of tau protein is a unifying theme in a multitude of neurodegenerative diseases, collectively called tauopathies. Missense mutations in the tau gene (MAPT) correlate with aggregation propensity and cause dominantly inherited tauopathies, but the molecular mechanism of how they …
-
Peptide-based inhibitors of tau aggregation as a potential therapeutic for Alzheimer’s disease
Tauopathies are a group of neurodegenerative diseases characterized by the deposition of misfolded and aggregated Tau protein in patients’ brains. Alzheimer's disease (AD), the most common tauopathy and leading cause of dementia, affects over 55 million people worldwide, with prevalence projected …
-
Characterization of Oxidized Tau Protein Aggregation and Inhibition of Tau Aggregation via MAP2
… composed of the microtubule stabilizing protein Tau are a pathological hallmark of Alzheimer's disease (AD) and many other dementia related diseases specified as Tauopathies. Due to alternative mRNA splicing, intrinsically disordered Tau exists as six separate isoforms in the adult human brain …
-
DEVELOPMENT OF AN IN-VITRO HUMANIZED MICROFLUIDIC PLATFORM TO STUDY NEURONAL TAU AGGREGATION AND PROPAGATION
… neurofibrillari (NFTs) formati dalla proteina tau iperfosforilata. Poiché è stato dimostrato che il declino cognitivo dei pazienti di AD correla con la diffusione degli aggregati di tau più che con la presenza di -amiloide, è fondamentale capire i meccanismi molecolari che causano la …
-
The development of peptide-based inhibitors for Tau aggregation as a potential therapeutic for Alzheimer’s disease
… main proteins that misfolds in this disease is Tau protein, which aggregates into toxic oligomers and neurofibrillary tangles. It is these aggregates, which cause damage to the brain resulting in dementia. As a result, it is imperative to be able to prevent or suppress the pathogenic aggregation …
-
Tauopathy in a Worm: Establishing and Applying a C. elegans Model for Studying Age-Linked Tau Aggregation
… group of neurodegenerative disorders called tauopathies. These disorders include Fronto-temporal dementia (FTD), Progressive Supranuclear Palsy (PSP), Pick’s Disease, and Corticobasal degeneration (CBD). Tauopathies are characterized by the accumulation of aggregated tau in neuronal and glial …
-
Investigation of a Tau aggregation inhibitor peptide and peptide-conjugated liposomes as a potential treatment for Alzheimer’s Disease
… alternative to Aβ, inhibiting the pathological aggregation of Tau has gained traction. Our group has recently developed a Tau aggregation inhibitor peptide, RI-AG03, to complement our Aβ aggregation inhibitor peptide RI-OR2. My aim in this thesis was to investigate the protective effects of …
-
Inhibition of Alzheimer’s type toxic aggregates of tau with fungal secondary metabolites
Tau is a microtubule-associated protein that is typically found in the axons of neurons. The aggregation of the tau is a significant event in many neurodegenerative diseases including Alzheimer's disease. In these disease tau dissociates from microtubules and begins to form toxic insoluble …
-
Cellular Mechanisms Governing Tau Propagation
Tau aggregation underlies neurodegenerative diseases called tauopathies such as Alzheimer's. Tau aggregates are amyloid assemblies that originate in one area and spread to other brain regions by being released and internalized by neighboring cells. In the recipient cell, tau aggregates can function …
-
Targeting Tau Degradation by Small Molecule Inhibitors for Treatment of Tauopathies
Tauopathies are neurodegenerative diseases that affect millions of people around the world. Tauopathies include more than 20 neurodegenerative diseases. Some of the most common tauopathies are Alzheimer’s disease (AD), frontotemporal dementia (FTD), chronic traumatic encephalopathy (CTE), Pick’s …
Page 1 of 5